FDA Brief

Warning letters Drugs

FDA warning letter to

iSlim, LLC

High riskIssued May 3, 2023Posted May 16, 2023Division of Pharmaceutical Quality Operations II

FDA warned iSlim, LLC that its Alfia Weight Loss Capsules are an unapproved, misbranded drug containing undeclared sibutramine.

What happened

FDA reviewed the website www.alfia.com in December 2022, where the company took orders for Alfia Weight Loss Capsules, and also obtained a sample and the product's labeling. Laboratory analysis of the sample found undeclared sibutramine, the active ingredient in the prescription weight-loss drug Meridia, which was withdrawn from the U.S. market in 2010 after data showed an increased risk of heart attack and stroke. The letter also notes the company declined to conduct a voluntary recall and that the product is no longer offered for sale on the website.

What FDA found

  1. The capsules are a new drug sold without the FDA approval the law requires.

    Sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d)
  2. The label does not give a lay person adequate directions for using the product safely.

    Section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1); 21 CFR 201.5, 201.100(c)(2), 201.115
  3. The labeling is false or misleading because it does not reveal that the product contains sibutramine.

    Sections 502(a) and 201(n) of the FD&C Act, 21 U.S.C. 352(a) and 321(n)
  4. The labeling lacks adequate warnings to protect people who take the product.

    Section 502(f)(2) of the FD&C Act, 21 U.S.C. 352(f)(2)
  5. The product is dangerous to health when used at the dose and in the way the label recommends.

    Section 502(j) of the FD&C Act, 21 U.S.C. 352(j)

What FDA wants

FDA asks the company to send a written response within fifteen working days of receiving the letter, explaining each step taken to fix the violations and to prevent them from happening again, with supporting documents. If the company believes it is not in violation, it must give its reasoning and evidence in the same timeframe.

Who should pay attention

  • online sellers and marketplaces listing imported weight-loss capsules
  • supplement brands that buy capsules from third-party suppliers
  • quality teams screening weight-loss products for hidden drug ingredients

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  2. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  3. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk
  4. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk